ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

ClinicalTrials.gov ID: NCT06248619

Public ClinicalTrials.gov record NCT06248619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease

Study identification

NCT ID
NCT06248619
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
89 participants

Conditions and interventions

Interventions

  • Placebo Other
  • Teprotumumab Biological

Other · Biological

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 4, 2024
Primary completion
Jan 13, 2026
Completion
Sep 1, 2026
Last update posted
Jan 27, 2026

2024 – 2026

United States locations

U.S. sites
11
U.S. states
11
U.S. cities
11
Facility City State ZIP Site status
Catalina Eye Care - NVISION - PPDS Tucson Arizona 85712
Advanced Quality Medical Research Orland Park Illinois 60462
W Kellogg Eye Center Ann Arbor Michigan 48105-1912
Las Vegas Endocrinology Henderson Nevada 89074
The Center for Eye and Facial Plastic Surgery Somerset New Jersey 08773
Casey Eye Institute -515 SW Campus Dr Portland Oregon 97239-3130
Scheie Eye Institute Philadelphia Pennsylvania 19104-2640
University of Tennessee Health Science Center - 848 Adams Ave Memphis Tennessee 38103-3452
Baylor College of Medicine-1977 Butler Blvd Houston Texas 77030-4101
University of Washington Eye Institute Seattle Washington 98104-2433
West Virginia University Eye Institute Morgantown West Virginia 26506-1200

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06248619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2026 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06248619 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →